Corrective Phases R...
Health Care: Drugs
Cellceutix Corporation (CTIX: OTC)
$0.57 0.02 | 3.64%
06/01/12 - 03:58 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 0.57 |
| 52 Week High | 0.82 |
| 52 Week Low | 0.25 |
| Avg. Daily Vol. (Mil) | 0.03 |
| Beta (3 year) | -0.39 |
| Share Related Items | |
| Mkt Cap (Mil) | 52.14 |
| Shares Out (Mil) | 91.48 |
| Float (Mil) | 44.28 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 0.00 |
| Current Ratio | 0.00 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 0.00 |
| Price/Cash Flow | -11.50 |
| Per Share Data | |
| Earnings | -0.04 |
| Sales | 0.00 |
| Book Value | 0.00 |
| Cash Flow | -0.05 |
| Business Summary | |
|---|---|
| The Company has seven (7) different pharmaceutical compound candidates that are designed for treatment of diseases which exist, or might exist in the future. | |
| General Information | |
| 187 Ballardvale Street
Suite A225 Wilmington, MA 01887 |
|
| www.cellceutix.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 2 | |
| CEO: Leo Ehrlich | |
| Short Interest | |
| Current Month (Mil) | 0.00 |
| Previous Month (Mil) | 0.00 |
| Short Interest Ratio (Days) | 0.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -4,589.00 |
| Return on Investments | 62.70 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with CTIX
- Portfolio NameUser Type
Latest CTIX Headlines from TheStreet
- Cheap Tickets Up as Cendant Extends Share Offer Deadline 09.24.01 | 08:09 am
- Cheap Tickets Tumbles on Warning 06.26.01 | 11:06 am
- The Daily Interview: Online Travel Skies Getting Crowded 06.13.01 | 10:06 am
- Ticker-Tape Parade: Cendant Buys Cheap Tickets, Semis Get an Upgrade 12.31.69 | 07:12 pm
- Cheap Tickets Leaps on Offer From Cendant 12.31.69 | 07:12 pm
Press Releases for CTIX
- Cellceutix CEO, Leo Ehrlich, Conducts Interview With "Biotech Stock Trader"; Dr. Paul Ginsberg, (Renowned Patent Attorney) Joins Cellceutix Advisory Board - PR Newswire 04.18.11 | 07:04 am
- Cellceutix Poster Presentation On Its P53 Cancer Breakthrough Attracts Wide Interest At 102nd AACR Meeting - PR Newswire 04.11.11 | 06:04 am
- Cellceutix Cancer Drug, Kevetrinâ¢, Shows Increased Levels Of P21; Biomarker For Cancer Trials - PR Newswire 03.31.11 | 08:03 am
- Cellceutix Announces That It Has Signed Confidential Disclosure Agreement For Its Autism Drug With Large Pharmaceutical Company - PR Newswire 03.28.11 | 07:03 am
- Cellceutix Anti-Cancer Breakthrough Selected For Poster Presentation At American Association For Cancer Research (AACR) - PR Newswire 03.21.11 | 07:03 am
- Cellceutix Reports Production Of Its Anti-Cancer Drug Kevetrin⢠Has Begun - PR Newswire 03.14.11 | 06:03 am
- Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company - PR Newswire 03.08.11 | 04:03 pm
- Cellceutix Discovers Drug Activates 'Guardian Angel P53' In Fight Against Leukemia - PR Newswire 03.07.11 | 07:03 am
- Cellceutix Cancer Drug Kevetrin⢠Shows No Genotoxicity In Study - PR Newswire 03.02.11 | 07:03 am
Partner Headlines for CTIX
